Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Medical care options in the form of a set of symbols in hands doctor.
Preclinical studies are an essential stage in a drug’s development journey as they help identify the appropriate dose range, potential side effects, and adverse reactions, and also provide a basis for regulatory approval.

Embracing Data-Driven Preclinical Drug Development

Having near real-time access to data boosts the efficiency of the drug development process

Kristen Eisenhauer, BS, EMBA

Kristen M. Eisenhauer began her career at Charles River in 2000 as a research technician at our Nevada safety assessment site and progressed through a number of technical positions of...

ViewFull Profile
Learn about ourEditorial Policies.
Published:May 23, 2023
|2 min read
Photo portrait of Kristen M. Eisenhauer
Kristen M. Eisenhauer, BS, EMBA, is the SVP, Commercial, Safety Assessment, which serves academic and biotechnology clients in Europe and North America, at Charles River. Eisenhauer holds a BS in health education from the University of Nevada and an EMBA from Suffolk University.

In today’s fast-paced and ever-evolving pharmaceutical industry, the demand for more efficient and effective drug development has never been greater. One of the major challenges facing drug developers is the need to streamline preclinical studies, which can be time-consuming and expensive.

Preclinical studies are an essential stage in a drug’s development journey—playing a pivotal role in identifying the appropriate dose range, potential side effects, and adverse reactions, and providing a basis for regulatory approval. These studies demand the contributions of skilled study directors, toxicologists, pathologists, veterinarians, regulatory specialists, and support personnel. 

On the front lines of drug development, it’s critical to ensure that products, services, and processes keep pace with the rapid evolution of science, technology, and the ever-changing needs of drug development.

That’s where data comes in. 

Data plays a critical role in preclinical studies 

Working at a global, nonclinical organization like Charles River Laboratories that partners with drug developers, data is central to the work we do for our customers. Regardless of what stage a biopharma company may be at with the drug, data is continuously informing the next step of its journey. Meaning, near real-time access to this kind of data can have a powerful impact.

By integrating technology-driven approaches into the preclinical process and improving access to study results and milestones, drug developers can use this insight to help inform important decisions that ultimately dictate a drug’s future. For example, secure, cloud-based platforms can be used to enhance drug development for industry clients, from the largest pharma companies to established and emerging biotech start-ups. 

Here are two ways to use data and technology more effectively:

  • Be open and agile: By remaining flexible, sharing information, and collaborating, teams can avoid duplicating work and identify potential issues early on. This can save time and resources and ultimately lead to faster development of new therapies.
  • Reduce friction: We need to completely reimagine how we work to generate faster insights. Leveraging all the capabilities of modern technology enables frictionless, digitally native processes.

Leveraging cutting-edge technology and providing greater access to data and tracking of milestones facilitates data-driven decision-making and boosts efficiency of the drug development process. As the pharmaceutical industry continues to evolve, a data-driven approach will play an increasingly important role in reshaping and future-proofing the drug industry.